Tipp

ASH 2014: novel strategies in the management of classical Hodgkin’s lymphoma

Zeitschrift:: memo - Magazine of European Medical Oncology > Ausgabe 3/2015

Autor:: MD Daniel Heintel

Abstract

This review discusses promising new approaches in the management of classical Hodgkin’s lymphoma that have been recently presented at the annual ASH meeting. Novel insights regarding risk-adapted, tailored therapy as well as improved treatment strategies in relapsed/refractory disease have been presented.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Jetzt informieren

Mounier N, Gisselbrecht C. Decision-making in the management of adult classical Hodgkin’s lymphoma: determining the optimal treatment. Expert Rev Hematol. 2015;8(2):205–16. CrossRefPubMed

Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52. CrossRefPubMed

Gallamini A, Barrington SF, Biggi A, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 2014;99(6):1107–13. PubMedCentralCrossRefPubMed

Mounier N, Brice P, Bologna S, Lymphoma Study Association (LYSA), et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Ann Oncol. 2014;25(8):1622–8. CrossRefPubMed

Federico M, Luminari S, Iannitto E, HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009;27(5):805–11. CrossRefPubMed

Viviani S, Zinzani PL, Rambaldi A, Michelangelo Foundation, Gruppo Italiano di Terapie Innovative nei Linfomi, Intergruppo Italiano Linfomi et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203–12. CrossRefPubMed

Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14(10):943–52. CrossRefPubMed

Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9. PubMedCentralCrossRefPubMed

Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma. a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348–56. CrossRefPubMed

10.

Ansell SM Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89(7):771–9. CrossRefPubMed

11.

Moskowitz CH, Nimer SD, Zelenetz AD et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616–23. CrossRefPubMed

12.

Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119(7):1665–70. PubMedCentralCrossRefPubMed

Titel: ASH 2014: novel strategies in the management of classical Hodgkin’s lymphoma
Autor:: MD Daniel Heintel
Publikationsdatum: 01.09.2015
DOI: https://doi.org/10.1007/s12254-015-0230-8
Verlag: Springer Vienna
Zeitschrift: memo - Magazine of European Medical Oncology An International Journal for Oncology and Haematology Professionals
Ausgabe 3/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Weitere Artikel der Ausgabe 3/2015

Prognostic factors and their correlation with staging in patients with multiple myeloma: a single centre study in North India

ASH 2014 highlights: new therapeutic concepts for T cell lymphomas

“Just because your doctor has a name for your condition doesn’t mean he knows what it is.” Bertrand Russell

Highlights of the American Society of Hematology Meeting 2014: Hemostaseology

A 59-year-old patient with somatic type malignancy as a relapse of testicular tumor after 28 years

Chronic lymphocytic leukemia: ASH update 2014